Janene Jarrett
Nurse Practitioner · Fresno, CANPI 1396702544
Payments from drug & device makers
Across 183 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$469
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$437
- Johnson & Johnson$412
- Amgen$389
- Takeda Pharmaceuticals U.S.A., Inc.$254
- AstraZeneca$244
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,55397%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 26 | $469 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $437 |
| Johnson & Johnson | 15 | $412 |
| Amgen | 20 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $254 |
| AstraZeneca | 12 | $244 |
| AbbVie(2 entities) | 10 | $238 |
| UCB, Inc. | 9 | $197 |
| Coloplast | 7 | $149 |
| Ardelyx, Inc. | 7 | $132 |
| Astellas Pharma US Inc | 6 | $99 |
| Gilead | 5 | $83 |
| Boston Scientific | 3 | $75 |
| Novartis | 3 | $71 |
| Fresenius Kabi USA, LLC | 2 | $67 |
| Tolmar Pharmaceuticals, Inc. | 2 | $49 |
| Ironwood Pharmaceuticals, Inc | 3 | $42 |
| Lilly USA, LLC | 2 | $34 |
| Urogen Pharma, Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $29 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| Bioventus LLC | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Viiv Healthcare Company | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Merck | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
How this compares
$3,653 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 22 | $60,722 |
| LinzessLinaclotide | 58 | $41,476 |
| ViberziEluxadoline | 11 | $25,132 |
| Mesalamine | 17 | $10,379 |
| Famotidine | 320 | $4,105 |
| Lactulose | 86 | $3,427 |
| Dicyclomine Hcl | 115 | $3,275 |
| Lubiprostone | 19 | $2,404 |
| Sucralfate | 26 | $2,242 |
| Omeprazole | 183 | $1,830 |
| Hydroxychloroquine Sulfate | 31 | $1,144 |
| MethotrexateMethotrexate Sodium | 28 | $642 |
| Ondansetron OdtOndansetron | 40 | $360 |
| Pantoprazole Sodium | 27 | $335 |
| Metronidazole | 21 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Viberzi | $238 | $66,60969 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $437 | $60,72222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Fresno
- Erica BedstedFresno$194K
- Sonja GrowcottFresno$31K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.